Characteristic | Patients, no. (%) | Â | Â | Â | Patients, no. (%) | Â | Â |
---|---|---|---|---|---|---|---|
Overall cohort (n = 110) | Good neurological outcome (n = 48) | Poor neurological outcome (n = 62) | P-valueb | AHSI group (n = 64)a | PHSI group (n = 46)a | P-valueb | |
Age, median (IQR), y | 57.5 (38.0–69.0) | 58.5 (38.0–68.0) | 57.5 (41.8–69.0) | .75 | 57.5 (30.5–67.5) | 56.5 (48.3–72.3) | .25 |
Sex | Â | Â | Â | Â | Â | Â | Â |
Female | 30 (27.3) | 10 (20.8) | 20 (32.3) | .20 | 16 (25.0) | 14 (30.4) | .67 |
Male | 80 (72.7) | 38 (79.2) | 42 (67.7) | Â | 48 (75.0) | 32 (69.6) | Â |
CCI score, median (IQR) | 2 (0–4) | 2 (0–4) | 2 (0–4) | .69 | 2 (0–4) | 2 (1–4) | .34 |
Arrest characteristics | Â | Â | Â | Â | Â | Â | Â |
Witness | 61 (55.5) | 39 (81.3) | 22 (35.5) |  < 0.001 | 44 (68.8) | 17 (37.0) |  < 0.001 |
Bystander CPR | 77 (70.0) | 39 (81.3) | 38 (61.3) | .03 | 49 (76.6) | 28 (60.9) | .09 |
Shockable rhythm | 36 (32.7) | 30 (62.5) | 6 (9.7) |  < 0.001 | 33 (51.6) | 3 (6.5) |  < 0.001 |
Cardiac etiology | 42 (38.2) | 30 (62.5) | 12 (19.4) |  < 0.001 | 32 (50.0) | 10 (21.7) | .003 |
Low flow time, median (IQR), min | 20.0 (9.5–30.0) | 12.5 (8.0–18.8) | 29.5 (20.5–43.0) |  < 0.001 | 15.0 (9.0–18.8) | 27.5 (20.0–39.8) |  < 0.001 |
Post-cardiac arrest care | Â | Â | Â | Â | Â | Â | Â |
Target temperature, 33 °C | 98 (89.1) | 40 (83.3) | 58 (93.5) | .12 | 56 (87.5) | 42 (91.3) | .76 |
Early PCI, n (%) | 9 (8.2) | 6 (12.5) | 3 (4.8) | .18 | 9 (14.1) | 0 | .01 |
Seizure before MRI, n (%) | 28 (25.5) | 12 (25.0) | 16 (25.8) | .96 | 20 (31.3) | 8 (17.4) | .12 |
Laboratory results after ROSC, median (IQR) | Â | Â | Â | Â | Â | Â | Â |
pH | 7.20 (7.06–7.30) | 7.25 (7.13–7.34) | 7.14 (7.00–7.27) | .004 | 7.25 (7.13–7.33) | 7.12 (6.99–7.23) |  < 0.001 |
Lactic acid, mmol/L | 8.2 (4.5–11.0) | 7.0 (3.6–10.4) | 8.7 (4.2–11.0) | .07 | 7.0 (4.0–7.0) | 9.8 (6.4–11.0) | .03 |
Times to examinations, median (IQR), h | Â | Â | Â | Â | Â | Â | Â |
ROSC to CT, 95c | 1.3 (0.7–2.2) | 1.1 (0.6–1.8) | 1.5 (0.9–2.4) | .17 | 1.1 (0.5–1.7) | 1.0 (0.3–1.8) | .30 |
ROSC to MRI | 2.8 (2.0–4.0) | 2.6 (1.9–3.8) | 2.9 (2.0–4.1) | .42 | 2.0 (1.6–3.3) | 2.8 (1.9–5.8) | .42 |
ROSC to obtain biomarker samples | 4.6 (3.4–6.0), 84c | 4.1 (3.2–5.8), 35c | 4.7 (4.0–6.0), 49c | .13 | 3.3 (3.0–5.6), 47c | 4.7 (3.2–5.9), 37c | .17 |
Neuro-prognostication, median (IQR) | Â | Â | Â | Â | Â | Â | Â |
Presence of HSI on DW-MRI, n (%) | 46 (41.8) | 0 | 46 (74.2) |  < 0.001 |  |  |  |
Serum NSE, ng/mL | 32.0 (21.8–57.6) | 25.2 (19.2–32.2) | 61.3 (42.1–152.8) |  < 0.001 | 25.2 (19.2–32.2) | 61.3 (42.1–152.8) |  < 0.001 |
CSF NSE, ng/mL, 89c | 44.4 (20.2–130.5) | 23.5 (15.6–47.4) | 130.0 (58.0–213.0) |  < 0.001 | 23.5 (15.6–47.4) | 130.0 (58.0–213.0) |  < 0.001 |
Average ADC value, × 10−6 mm2/s | 828.3 (774.6–853.4) | 847.3 (829.4–867.4) | 783.2 (647.5–829.2) |  < 0.001 | 843.2 (828.4–865.4) | 764.3 (593.1–806.7) |  < 0.001 |
PV 650, % | 17.1 (12.1–29.2) | 13.2 (10.3–17.0) | 31.1 (23.2–66.3) |  < 0.001 | 13.2 (10.3–17.0) | 31.1 (23.2–66.3) |  < 0.001 |
GWR, 95c | 1.22 (1.16–1.28) | 1.23 (1.19–1.30) | 1.20 (1.11–1.25) |  < 0.001 | 1.24 (1.19–1.30) | 1.20 (1.11–1.25) | .005 |
Low flow time, min | 20.0 (10.0–30.0) | 14.0 (8.0–20.8) | 30.5 (22.8–44.5) |  < 0.001 | 14.0 (8.0–20.8) | 30.5 (22.8–44.5) |  < 0.001 |
QA, 89c | 0.008 (0.006–0.013) | 0.007 (0.005–0.009) | 0.011 (0.008–0.019) |  < 0.001 | 0.007 (0.005–0.009) | 0.011 (0.008–0.019) |  < 0.001 |
Outcome |  |  |  |  < 0.001 |  |  |  < 0.001 |
Survival | 76 (69.7) | 48 (100) | 29 (46.8) | Â | 60 (95.2) | 16 (34.8) | Â |
Brain death | 12 (11.0) | 0 | 12 (19.4) | Â | 1 (1.6) | 11 (23.9) | Â |
WLST after 72Â h from ROSC | 6 (5.5) | 0 | 6 (9.7) | Â | 0 | 6 (13.0) | Â |